Abatacept in psoriatic arthritis: Case report and short review

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Ursini, Francesco ^a   Naty, Saverio ^a   Russo, Emilio ^a   Grembiale, Rosa ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Abatacept; psoriasis; psoriatic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADULT; ASTHENIA; BRONCHITIS; CASE REPORT; COUGHING; DENDRITIC CELL; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GLOTTIC EDEMA; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INFLUENZA; KERATINOCYTE; MEDICAL HISTORY; MIDDLE AGED; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL; PHARYNGITIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SOMNOLENCE; SORE THROAT; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VASCULAR DISEASE; VOMITING;

EID: 84889565373     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120943     Document Type: Review

References (33)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
2. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
3. Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther 2005;7 Suppl 2:S21-5.
4. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006;5:185-6.
5. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-75.
6. Green JM, Karpitskiy V, Kimzey SL, Shaw AS. Coordinate regulation of T cell activation by CD2 and CD28. J Immunol 2000;164:3591-5.
7. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
8. Chambers CA, Allison JP. CTLA-4-the costimulatory molecule that doesn't: Regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 1999;64:303-12.
9. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162-6.
10. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012;9:302-9.
11. Choy E. T cells in psoriatic arthritis. Curr Rheumatol Rep 2007;9:437-41.
12. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: Implications for treatment. Ann Rheum Dis 2006;65:1551-7.
13. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006;54:1638-45.
14. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
15. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyteassociated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
16. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
17. Canete JD, Celis R, Hernandez V, Pablos JL, Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2010;69:935-6.
18. Rodrigues CE, Vieira FJ, Callado MR, Gomes KW, de Andrade JE, Vieira WP, Use of the abatacept in a patient with psoriatic arthritis. Rev Bras Reumatol 2010;50:340-5.
19. Altmeyer MD, Kerisit KG, Boh EE. Therapeutic hotline. Abatacept: Our experience of use in two patients with refractory psoriasis and psoriatic arthritis. Dermatol Ther 2011;24:287-90.
20. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(5 Suppl 46):S46-56.
21. Jost C, Hermann J, Caelen Lel-S, Graninger W. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep 2009; doi:10.1136/bcr.09.2008.0845.
22. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol 2010;90:183-5.
23. Florent A, Albert C, Giacchero D, Roux C, Euller-Ziegler L. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010;77:626-7.
24. Kato K, Satoh T, Nishizawa A, Yokozeki H, Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 2011;91:362-3.
25. Brigant F, Clavel G, Chatelain D, Lok C, Chaby G. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J 2011;17:11.
26. Silverman D, Oliver A. Abatacept-induced psoriasis. Cutis 2011;88:117-8.
27. Konsta M, Rallis E, Karameris A, Stratigos A, Sfikakis PP, Iliopoulos A. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol 2012;26:257-8.
28. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther 2005;7:R666-76.
29. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
30. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
31. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
32. Lekpa FK, Farrenq V, Canoui-Poitrine F, Paul M, Chevalier X, Bruckert R, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012;79:47-50.
33. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10.